Latest News for: efficacy
Edit
Research Partnership to Quantify Efficacy Maritime Training Immersive Tech
The Maritime Executive 16 May 2026
The University of Plymouth (UK), Odesa National Maritime University (Ukraine), and Kilo Solutions Ltd have launched a joint research project focused o ....
Edit
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA� (darolutamide) ...
Business Wire 16 May 2026
Edit
Caledonian Record
15 May 2026
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal
... potent preclinical efficacy and differentiated safety ....
Edit
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways ...
Nasdaq Globe Newswire 15 May 2026
- REX-8756 is an oral, first-in-class orthosteric ...
Edit
The Joplin Globe
15 May 2026
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) ...
Edit
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
Pharmiweb 15 May 2026
Edit
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
PR Newswire 14 May 2026
Edit
Reference 2 - Kalaria SN, TR Farchione, R Uppoor, M Mehta, Y Wang, and H Zhu, 2021, Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder, Journal of Clinical Pharmacology, 61: S117–S124, doi: 10.1002/jcph.1836. (The eRulemaking Program)
Public Technologies 13 May 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 131737899) .
Edit
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & Korsinsky
PR Newswire 13 May 2026
Key Dates and Disclosure Events Shareholders Need to Know ... (NASDAQ. IBRX) to contact the firm ... Levi, Esq ... The drug's efficacy was established only in combination with BCG, and a cohort studying ANKTIVA as a single agent was stopped early for futility ... Q ... .
Edit
The Daily Record - Dunn
12 May 2026
Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With ...
Edit
28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy
PR Newswire 12 May 2026
The only assay-ready 3D brain organoid model to quantify myelin loss, natural recovery, and dose-dependent remyelination. Advances the ability to model human pathogenesis and functional recovery for neurodegenerative diseases ... About 28bio ... References ... .
Edit
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001 (Forbion Capital Partners Management Services BV)
Public Technologies 12 May 2026
The trial aimed to investigate the efficacy, safety, tolerability and pharmacokinetics of inhaled ETD001 in the 10% of people with CF (pwCF) with the highest unmet medical need, who do not benefit from treatment with CFTR modulators.
Edit
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001 (IP Group plc)
Public Technologies 12 May 2026
The trial aimed to investigate the efficacy, safety, tolerability and pharmacokinetics of inhaled ETD001 in the 10% of people with CF (pwCF) with the highest unmet medical need, who do not benefit from treatment with CFTR modulators.
Edit
TOMI Environmental Solutions Highlights SteraMist Efficacy in Neutralizing Biohazards Amid Rising Hantavirus Concerns
Nasdaq Globe Newswire 08 May 2026- 1
- 2
- Next page »